Feed SONN
SO
Sonnet BioTherapeutics Holdings, Inc. SONN NASDAQ · Healthcare · United States
$1.26 -59.35% -$1.84
Summary
22 / 100 · Bulios Score
Valuation 0Growth 0Profitability 0Quality 41Debt 70Stability 25
What speaks for it
- It earns 489 USD a year on every 100 USD of invested capital.
- It could repay all its net debt from 0.0 years of operating profit.
What to watch
- Revenue fell by 66% a year over the last 3 years.
- The company made a loss over the last 12 months.
- It passes only 2 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
201820262027
- Analyst estimate
Revenue fell by 66% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Cash and short-term investments $524.1K
Debt $10.3M
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.